75N93024C00087
Definitive Contract
Overview
Government Description
FURTHER CHARACTERIZATION AND VALIDATION OF MONOCLONAL ANTIBODIES TO STUDY RESPIRATORY
Awardee
Awarding / Funding Agency
Place of Performance
Lake Clear, NY 12945 United States
Pricing
Fixed Price
Set Aside
None
Extent Competed
Full And Open Competition
Related Opportunity
PHS202401
Ampersand Biosciences was awarded
Definitive Contract 75N93024C00087 (75N930-24-C-00087)
for Further Characterization And Validation Of Monoclonal Antibodies To Study Respiratory
worth up to $1,084,824
by the National Institute of Allergy and Infectious Diseases
in September 2024.
The contract
has a duration of 2 years and
was awarded
full & open
with
NAICS 541714 and
PSC AN12
via direct negotiation acquisition procedures with 12 bids received.
Status
(Open)
Last Modified 1/3/25
Period of Performance
9/30/24
Start Date
9/29/26
Current End Date
9/29/26
Potential End Date
Obligations
$1.1M
Total Obligated
$1.1M
Current Award
$1.1M
Potential Award
Award Hierarchy
Definitive Contract
75N93024C00087
Subcontracts
Activity Timeline
Labor Services Billing
Annual labor billing rates and FTE reported for 75N93024C00087
| Year | Services Invoiced | Hours | FTE | Blended Rate |
|---|---|---|---|---|
| 2024 | $90,402 | 415.0 | 0.2 | $217.84 |
Transaction History
Modifications to 75N93024C00087
People
Suggested agency contacts for 75N93024C00087
Competition
Number of Bidders
12
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No
Other Categorizations
Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
HLWQXLFM7JR8
Awardee CAGE
79VC0
Agency Detail
Awarding Office
75N930 NATIONAL INSTITUTES OF HEALTH NIAID
Funding Office
75N930
Created By
hhsmpham
Last Modified By
hhsedubbaneh
Approved By
hhsedubbaneh
Legislative
Legislative Mandates
None Applicable
Performance District
NY-21
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Representative
Elise Stefanik
Modified: 1/3/25